The safety of hydroquinone

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 7, 2006, Pages 781-787

  Nordlund, J J ^a,b   Grimes, P E ^c,e   Ortonne, J P ^d  

^a WRIGHT STATE UNIVERSITY   (United States)

^b Group Health Associates   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e NONE   (United States)

Author keywords

Hydroquinone; Hyperpigmentation; Safety

Indexed keywords

ARBUTIN; BENZENE DERIVATIVE; COSMETIC; DEXAMETHASONE; HERBACEOUS AGENT; HYDROQUINONE; RETINOIC ACID;

CARCINOGENICITY; CHLOASMA; CHRONIC DISEASE; CONJUNCTIVA DISEASE; CORNEA DISEASE; CORNEA DYSTROPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; ERYTHEMA; EYE DISEASE; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; IRRITANT DERMATITIS; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DOCUMENTATION; MELANOSIS; MUTAGENICITY; NAIL DISEASE; OCHRONOSIS; PAPULE; PRIORITY JOURNAL; REVIEW; SKIN ALLERGY; SKIN CANCER; SKIN NODULE;

ANIMALS; COSMETICS; HUMANS; HYDROQUINONES; HYPERPIGMENTATION; OCCUPATIONAL EXPOSURE; PHYTOTHERAPY; SAFETY;

EID: 33746310932     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01670.x     Document Type: Review

References (73)

1. Balkrishnan R, Kelly AP, McMichael A et al. Improved quality of life with effective treatment of facial melasma: The pigment trial. J Drugs Dermatol 2004; 3: 377-381.
2. Balkrishnan R, McMichael A, Yu JY et al. Corrective cosmetics are effective for women with facial pigmentary disorders. Cutis 2005; 75: 181-187.
3. Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res 2003; 16: 101-110.
4. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol 1995; 131: 1453-1457.
5. Pandya A, Guevara I. Disorders of hyperpigmentation. Dermatol Clin 2000; 18: 91-98.
6. Katsambas AD. RALGA (Diacneal), a retinaldehyde and glycolic acid association and postinflammatory hyperpigmentation in acne - a review. Dermatology 2005; 210: 39-45.
7. Halder RM, Richards GM. Management of dyschromias in ethnic skin. Dermatol Ther 2004; 17: 151-157.
8. Rendon MI, Gaviria JI. Review of skin-lightening agents. Dermatol Surg 2005; 31: 886-889.
9. Kooyers T, Westerhof W. Toxicological aspects and health risks associated with hydroquinone in skin bleaching formula [article in Dutch]. Ned Tijdschr Geneeskd 2004; 148: 768-771.
10. Cummings M, Nordlund JJ. Chemical leukoderma: Fact or fancy. Am J Contact Dermatol 1995; 6: 122-127.
11. Oettel H. Hydroquinone poisoning. Arch Exp Pathol Pharmacol 1956; 183: 319-362.
12. Martin GJ, Ansbacher S. Confirmatory evidence of the chromotrichal activity of p-aminobenzoic acid. J Biol Chem 1941; 13: 441.
13. Denton CR. Skin protective agents. Med Bull (Ann Arbor) 1952; 18: 143-152.
14. Lerner AB, Fitzpatrick TB. Treatment of melanin hyperpigmentation. J Am Med Assoc 1953; 152: 577-582.
15. Spencer MC. Hydroquinone bleaching. Arch Dermatol 1961: 84.
16. Arndt KA, Fitzpatrick TB. Topical use of hydroquinone as a depigmenting agent. J Am Med Assoc 1965; 194: 965-967.
17. Kligman A, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975; 111: 40-48.
18. Sanchez JL, Vazquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol 1982; 21: 55-58.
19. Verallo-Rowell VM, Verallo V, Graupe K et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol (Stockh) 1989: 58-61.
20. Belina LM, Graupe K. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991; 30: 893-895.
21. Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: A clinical comparison with hydroquinone. Clin Ther 1998; 20: 960-970.
22. Haddad AL, Matos LF, Brunstein F et al. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs placebo in the treatment of melasma. Int J Dermatol 2003; 42: 153-156.
23. Astaneh R, Farboud E, Nazemi MJ. 4% Hydroquinone versus 4% hydroquinone, 0.05% dexamethasone and 0.05% tretinoin in the treatment of melasma: A comparative study. Int J Dermatol 2005; 44: 599-601.
24. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol 2003; 42: 966-972.
25. Taylor SC, Torok H, Jones T et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003; 72: 67-72.
26. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis 2004; 74: 362-368.
27. Torok HM, Jones T, Rich P et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: A safe and efficacious 12-month treatment for melasma. Cutis 2005; 75: 57-62.
28. Pathak MA, Fitzpatrick TB, Krause EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol 1986; 15: 849-894.
29. DeCaprio AP. The toxicology of hydroquinone - relevance to occupational and environmental exposure. Crit Rev Toxicol 1999; 29: 283-330.
30. Findlay GH, Morrison JGL, Simson IW. Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams. Br J Dermatol 1975; 93: 613-622.
31. Cullison D, Abele DC, O'Quinn JL. Localized exogenous ochronosis. Report of a case and review of the literature. J Am Acad Dermatol 1983; 8: 882-889.
32. Hardwick N, Van Gelder LW, Van Der Merwe CA et al. Exogenous ochronosis: an epidemiological study. Br J Dermatol 1989; 12: 229-238.
33. Hoshaw RA, Zimmerman KG, Menter A. Ochronosis-like pigmentation from hydroquinone bleaching creams in American Blacks. Arch Dermatol 1985; 121: 105-108.
34. Lawrence N, Bligard CA, Reed R et al. Exogenous ochronosis in the United States. J Am Acad Dermatol 1988; 18: 1207-1211.
35. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2: 213-217.
36. Phillips JI, Isaacson C, Carman H. Ochronosis in Black South Africans who used skin lighteners. Am J Dermatopathol 1986; 8: 14-21.
37. Garcia RL, White JW, Willis WF. Hydroquinone nail pigmentation. Arch Dermatol 1978; 114: 1402-1403.
38. Mann RJ, Harman RRM. Nail staining due to hydroquinone skin-lightening creams. Br J Dermatol 1983; 108: 363-365.
39. Anderson B. Corneal and conjunctival pigmentation among workers engaged in the manufacture of hydroquinone. Arch Ophthalmol 1947; 38: 812-825.
40. Naumann G. Corneal damage in hydroquinone workers. Arch Ophthalmol 1966; 76: 189-194.
41. Kari FW, Bucher J, Eustis SL et al. Toxicity and carcinogenicity of hydroquinone in F344/N rats and B6C3F1 mice. Food Chem Toxicol 1992; 30: 737-747.
42. Hydroquinone. IARC Monogr Eval Carcinog Risks Hum 1999; 71: 691-719.
43. Devillers J, Boule P, Vasseur P et al. Environmental and health risks of hydroquinone. Ecotoxicol Environ Safety 1990; 19: 327-354.
44. Robertson ML, Eastmond DA, Smith MT. Two benzene metabolites, catechol and hydroquinone, produce a synergistic induction of micronuclei and toxicity in cultured human lymphocytes. Mutat Res 1991; 249: 201-209.
45. Yager JW, Eastmond DA, Robertson ML et al. Characterization of micronuclei induced in human lymphocytes by benzene metabolites. Cancer Res 1990; 50: 393-399.
46. Doepker CL, Dumont KW, O'Donoghue J, English JC. Lack of induction of micronuclei in human peripheral blood lymphocytes treated with hydroquinone. Mutagenesis 2000; 15: 479-487.
47. Roza L, de Vogel N, van Delft JH. Lack of clastogenic effects in cultured human lymphocytes treated with hydroquinone. Food Chem Toxicol 2003; 41: 1299-1305.
48. Fabiani R, De Bartolomeo A, Rosignoli P et al. Influence of culture conditions on the DNA-damaging effect of benzene and its metabolites in human peripheral blood mononuclear cells. Environ Mol Mutagen 2001; 37: 1-6.
49. Reddy MV, Bleicher WT, Blackburn GR, Mackerer CR. DNA adduction by phenol, hydroquinone, or benzoquinone in vitro but not in vivo: Nuclease P1-enhanced 32 P-postlabeling of adducts as labeled nucleoside bisphosphates, dinucleotides and nucleoside monophosphates. Carcinogenesis 1990; 11: 1349-1357.
50. Corley RA, English JC, Hill TS et al. Development of a physiologically based pharmacokinetic model for hydroquinone. Toxicol Appl Pharmacol 2000; 165: 163-174.
51. Ciranni R, Barale R, Ghelardini G, Loprieno N. Benzene and the genotoxicity of its metabolites. II. The effect of the route of administration on the micronuclei and bone marrow depression in mouse bone marrow cells. Mutat Res 1988; 209: 23-28.
52. Neun DJ, Penn A, Snyder CA. Evidence for strain-specific differences in benzene toxicity as a function of host target cell susceptibility. Arch Toxicol 1992; 66: 11-17.
53. David RM, English JC, Totman LC et al. Lack of nephrotoxicity and renal cell proliferation following subchronic dermal application of a hydroquinone cream. Food Chem Toxicol 1998; 36: 609-616.
54. Deisinger PJ, Hill TS, English JC. Human exposure to naturally occurring hydroquinone. J Toxicol Environ Health 1996; 47: 31-46.
55. Quintus J, Kovar KA, Link P, Hamacher H. Urinary excretion of arbutin metabolites after oral administration of bearberry leaf extracts. Planta Med 2005; 71: 147-152.
56. Saito T, Kojimahara M, Aoki K, Takeichi S. Detection of hydroquinone in a poisoning case. J Forensic Sci 1994; 39: 266-270.
57. Saito T, Takeichi S. Experimental studies on the toxicity of lithographic developer solution. J Toxicol Clin Toxicol 1995; 33: 343-348.
58. Barber ED, Hill T, Schum DB. The percutaneous absorption of hydroquinone (HQ) through rat and human skin in vitro. Toxicol Lett 1995; 80: 167-172.
59. Wester RC, Melendres J, Hui X et al. Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition. J Toxicol Environ Health 1998; 54: 301-317.
60. Friedlander BR, Hearne FT, Newman BJ. Mortality, cancer incidence, and sickness-absence in photographic processors: An epidemiologic study. J Occup Med 1982; 24: 605-613.
61. Liden C. Occupational dermatoses at a film laboratory. Contact Dermatitis 1984; 10: 77-87.
62. Nielsen H, Henriksen L, Olsen JH. Malignant melanoma among lithographers. Scand J Work Environ Health 1996; 22: 108-111.
63. Chavin W, Jelonek EJ Jr, Reed AH, Binder LR. Survival of mice receiving melanoma transplants is promoted by hydroquinone. Science 1980; 208: 408-410.
64. Pifer JW, Hearne FT, Friedlander BR, McDonough JR. Mortality study of men employed at a large chemical plant, 1972 through 1982. J Occup Med 1986; 28: 438-444.
65. Pifer JW, Hearne FT, Swanson FA, O'Donoghue JL. Mortality study of employees engaged in the manufacture and use of hydroquinone. Int Arch Occup Environ Health 1995; 67: 267-280.
66. Rinsky RA, Smith AB, Hornung R et al. Benzene and leukaemia. An epidemiologic risk assessment. N Engl J Med 1987; 316: 1044-1050.
67. Smith MT. Overview of benzene-induced aplastic anaemia. Eur J Haematol Suppl 1996; 60: 107-110.
68. Partanen T, Heikkila P, Hernberg S et al. Renal cell cancer and occupational exposure to chemical agents. Scand J Work Environ Health 1991;17: 231-239.
69. Medinsky MA, Schlosser PM, Bond JA. Critical issues in benzene toxicity and metabolism: The effect of interactions with other organic chemicals on risk assessment. Environ Health Perspect 1994; 102: 119-124.
70. Gaskell M, McLuckie KI, Farmer PB. Genotoxicity of the benzene metabolites para-benzoquinone and hydroquinone. Chem Biol Interact 2005; 153-154: 267-270.
71. Gut I, Nedelcheva V, Soucek P et al. Cytochrome P450 in benzene metabolism and involvement of their metabolites and reactive oxygen species in toxicity. Environ Health Perspect 1996; 104: 1211-1218.
72. Irons RD. Quinones as toxic metabolites of benzene. J Toxicol Environ Health 1985; 16: 673-678.
73. Kalf GF. Recent advances in the metabolism and toxicity of benzene. Crit Rev Toxicol 1987; 18: 141-159.